Jaffer Yasmin, Selby Nicholas M, Taal Maarten W, Fluck Richard J, McIntyre Christopher W
Department of Renal Medicine, Derby City Hospital, UK.
Am J Kidney Dis. 2008 Feb;51(2):233-41. doi: 10.1053/j.ajkd.2007.10.038.
Catheter-related infection (CRI) is associated with increased all-cause mortality and morbidity in hemodialysis patients and may be reduced by using antimicrobial lock solutions (ALSs).
We performed a meta-analysis of studies identified from a search conducted in February 2007 of the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature, databases of ongoing trials, major renal journals, and reference lists of relevant reports.
SETTING & POPULATION: Patients receiving acute or long-term hemodialysis through a tunneled or nontunneled central venous catheter.
We included all prospective randomized studies that compared ALS with heparin.
Administration of antibiotic and/or antimicrobial catheter locking solution.
Primary outcome was CRI rate in patients using ALSs compared with those using heparin alone. We also examined effects of ALS use on mortality, adverse events, and catheter thrombosis.
7 studies were identified with a total of 624 patients and 819 catheters (448 tunneled, 371 nontunneled). CRI was 7.72 (95% confidence interval, 5.11 to 10.33) times less likely when using ALS. There were no consistent suggestions of adverse outcomes with ALS use; in particular, rates of catheter thrombosis did not increase. There was no evidence of antibiotic resistance developing during a maximum follow-up of 12 months.
The major limitation of this review is the relatively short duration of follow-up of the included studies, which does not allow complete reassurance regarding the development of antibiotic resistance. Lack of direct comparisons means that determination of the most efficient ALS is not possible.
This review confirms that antibiotic locking solutions reduce the frequency of CRI without significant side effects.
导管相关感染(CRI)与血液透析患者全因死亡率和发病率增加相关,使用抗菌封管溶液(ALSs)可能会降低其发生率。
我们对2007年2月在Cochrane对照试验中央登记册、MEDLINE、EMBASE、护理及相关健康文献累积索引、正在进行的试验数据库、主要肾脏期刊以及相关报告的参考文献列表中检索到的研究进行了荟萃分析。
通过隧道式或非隧道式中心静脉导管接受急性或长期血液透析的患者。
我们纳入了所有比较ALS与肝素的前瞻性随机研究。
给予抗生素和/或抗菌导管封管溶液。
主要指标是使用ALS的患者与仅使用肝素的患者的CRI发生率。我们还研究了使用ALS对死亡率、不良事件和导管血栓形成的影响。
共纳入7项研究,涉及624例患者和819根导管(448根隧道式,371根非隧道式)。使用ALS时CRI发生的可能性降低了7.72倍(95%置信区间,5.11至10.33)。没有一致的证据表明使用ALS会产生不良后果;特别是,导管血栓形成的发生率没有增加。在最长12个月的随访期间,没有证据表明会出现抗生素耐药性。
本综述的主要局限性是纳入研究的随访时间相对较短,这无法完全确定抗生素耐药性的发展情况。缺乏直接比较意味着无法确定最有效的ALS。
本综述证实抗菌封管溶液可降低CRI的发生率,且无明显副作用。